Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second versus first wave of COVID-19 in patients with MPN.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: masciulli a. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21. Leukemia. 2022. PMID: 35064223 Free PMC article. No abstract available.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Guglielmelli P, et al. Among authors: masciulli a. Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1. Blood. 2011. PMID: 21725052 Free PMC article. Clinical Trial.
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.
Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Pennucci V, et al. Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. Epub 2014 Jun 16. Leuk Lymphoma. 2015. PMID: 24707949 No abstract available.
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T. Scherber RM, et al. Among authors: masciulli a. Leuk Lymphoma. 2017 Jun;58(6):1481-1487. doi: 10.1080/10428194.2016.1246733. Epub 2016 Nov 10. Leuk Lymphoma. 2017. PMID: 27830999 Free PMC article.
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, Colagrande S, Castellani A, Masciulli A, Rosti V, De Stefano V, Betti S, Finazzi G, Ferrari ML, Rumi E, Ruggeri M, Nichele I, Guglielmelli P, Fjerza R, Mannarelli C, Fanelli T, Merli L, Corbizi Fattori G, Massa M, Cimino G, Rambaldi A, Barosi G, Cazzola M, Barbui T, Vannucchi AM. Pieri L, et al. Among authors: masciulli a. Am J Hematol. 2017 Feb;92(2):187-195. doi: 10.1002/ajh.24614. Am J Hematol. 2017. PMID: 27880982 Free article. Clinical Trial.
ACE inhibitors and cytoreductive therapy in polycythemia vera.
Barbui T, Masciulli A, Ghirardi A, Carobbio A. Barbui T, et al. Among authors: masciulli a. Blood. 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. Epub 2016 Dec 27. Blood. 2017. PMID: 28028024 Free article. No abstract available.
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.
Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: masciulli a. Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. Haematologica. 2017. PMID: 28255021 Free PMC article. Review. No abstract available.
52 results